Skip to main content

Table 4 Adjusted odds ratios and 95% confidence intervals for between-treatment comparisons*

From: Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients

LDL-C < 100 mg/dL 5.29 (4.79, 5.84)
non-HDL-C < 130 mg/dL 5.08 (4.59, 5.61)
Apo B < 90 mg/dL 3.30 (2.98, 3.64)
hs-CRP < 2 mg/L 1.22 (1.12, 1.34)
hs-CRP < 1 mg/dL 1.26 (1.15, 1.39)
LDL-C < 100 & non-HDL-C < 130 mg/dL 5.18 (4.70, 5.70)
LDL-C < 100 & Apo B < 90 mg/dL 3.34 (3.02, 3.69)
LDL-C < 100 & hs-CRP < 2 mg/L 2.52 (2.30, 2.77)
LDL-C < 100 & hs-CRP < 1 mg/L 2.05 (1.84, 2.28)
  1. Apo = Apolipoprotein; EZ = ezetimibe; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; hs-CRP = high-sensitivity C-reactive protein
  2. *Ratio of the predictive odds of attaining target on Statin+EZ versus statin based on the logistic model with terms for first/second line, treatment, and baseline value(s).